Is Parkinson's disease genetic, or is it Lewy body dementia?

Both Parkinson's Disease and Lewy Body Dementia Have Genetic Components

Both Parkinson's disease (PD) and dementia with Lewy bodies (DLB) have genetic factors contributing to their development, and they share overlapping genetic risk factors as part of the Lewy body disease spectrum. These are not mutually exclusive conditions—they exist on a continuum of α-synuclein-associated diseases 1.

Understanding the Genetic Overlap

Shared Genetic Architecture

Both conditions share common genetic risk factors:

• GBA1 mutations: Present in both PD and DLB, with carriers showing greater Lewy body burden (OR 1.94) 2
• SNCA gene: Associated with both conditions, as both are synucleinopathies 3
• APOE E4 allele: Shared risk factor linking both to Alzheimer's disease pathology 3
• TMEM175: Recently identified as a shared genetic risk factor between PD and DLB, with downregulation seen in both conditions 4
• LRRK2 mutations: Associated with PD, though interestingly only 59% of LRRK2 cases show Lewy body pathology at autopsy 2

Key Distinction in Pathology

The critical finding is that Lewy body pathology is not universally present in genetic PD 2:

• 98% of GBA mutation carriers have Lewy bodies
• 59% of LRRK2 mutation carriers have Lewy bodies
• Only 32% of PARKIN-related PD cases have Lewy bodies

This challenges the assumption that all genetic PD follows the same pathological pathway and has major implications for synuclein-based biomarker development 2.

Clinical Implications

The Disease Spectrum Concept

DLB and PD with dementia (PDD) are best understood as extremes on a continuum rather than separate diseases 5. They share:

• α-synuclein/Lewy body pathology (predominantly composed of alpha-synuclein and ubiquitin) 1
• Clinical features: cognitive impairment, parkinsonism, visual hallucinations, fluctuating attention 5
• Genetic risk factors 6
• Response to cholinesterase inhibitors 7

Distinguishing Features

The main clinical distinction is timing of symptom onset:

• DLB: Cognitive impairment appears early, within 1 year of motor symptoms
• PDD: Cognitive impairment develops later, after established motor symptoms 5

Pathologically, DLB shows:

• More pronounced cortical atrophy
• Higher cortical and limbic Lewy body burden
• Greater Aβ and tau loads in cortex and striatum
• Earlier cognitive deficits 5

Ancestry-Related Differences

Genetic ancestry influences pathological presentation 8:

• South Asian donors show higher rates of progressive supranuclear palsy pathology
• Ashkenazi Jewish donors show higher rates of Lewy body disease (independent of GBA1/LRRK2 status)

Critical Pitfalls to Avoid

1. Don't assume all genetic PD has Lewy bodies: PARKIN and LRRK2 mutations frequently lack Lewy body pathology, which has major implications for clinical trial enrollment and biomarker interpretation 2

2. Don't overlook Alzheimer's co-pathology: 40% of Lewy body disease cases have concurrent Alzheimer's pathology, which significantly impacts cognitive symptoms 8

3. Don't ignore incidental Lewy body disease: 4.4% of neurologically normal controls have Lewy pathology at autopsy, suggesting a preclinical phase 8

4. Lewy body pathology correlates with clinical features: Cases with Lewy bodies show later disease onset (54.6 vs 44.7 years), shorter disease duration (14.8 vs 27.7 years), and 15.9-fold higher odds of cognitive impairment 2

Practical Clinical Approach

When evaluating a patient with parkinsonism and/or dementia:

• Consider genetic testing for GBA1, LRRK2, SNCA, and PARKIN, particularly with:

  • Early-onset disease (<50 years)
  • Family history
  • Ashkenazi Jewish ancestry (higher GBA1 prevalence)

• Recognize that genetic results don't predict pathology perfectly: A LRRK2 mutation doesn't guarantee Lewy body pathology

• Understand that both conditions represent a spectrum: The arbitrary 1-year rule distinguishing DLB from PDD is clinically useful but biologically artificial 5